YSYvonne Stoll

Yvonne Stoll

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yvonne Stoll has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Andrea Rabenstein

    Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Munich, Germany

    3 shared publications
  • Andreas Luch

    Department of Chemical & Product Safety, German Federal Institute for Risk Assessment (BfR), Max-Dohrn-Strasse 8-10, 10589 Berlin, Germany

    3 shared publications
  • Elke Pieper

    German Federal Institute for Risk Assessment (BfR), Department of Chemical and Product Safety, Max-Dohrn-Straße 8, 10589 Berlin, Germany

    3 shared publications
  • Peter Laux

    Department of Chemical and Product Safety, German Federal Institute for Risk Assessment (BfR), Max-Dohrn-Strasse 8-10, 10589 Berlin, Germany

    3 shared publications
  • Tobias Rüther

    Department of Psychiatry and Psychotherapy, LMU University Hospital Munich, Munich, Germany

    3 shared publications
  • Anna Rahofer

    Department of Psychiatry and Psychotherapy, University Hospital of the Ludwig-Maximilians-University Munich (LMU) Munich, Special Outpatient Clinic for Tobacco Dependence, Nußbaumstraße 7, 80336 Munich, Germany

    2 shared publications

Latest Publications

  • Open Access

    Smoking Topography, Nicotine Kinetics, and Subjective Smoking Experience of Mentholated and Non-Mentholated Heated Tobacco Products in Occasional Smokers

    by Benedikt Rieder, Yvonne Stoll, Christin Falarowski, Marcus Gertzen, Gabriel Kise, Gabriele Koller, Sarah Koch, Peter Laux, Andreas Luch, Anna Rahofer, et al.

    Background: Heated tobacco products (HTPs) are marketed as reduced-harm alternatives to conventional cigarettes (CCs) and are increasingly used by young adults and occasional smokers. However, their acute nicotine delivery and user experience remain insufficiently studied in occasional smokers without established cigarette or nicotine dependence. Additives such as menthol—known to reduce sensory irritation and facilitate inhalation—may further influence initiation and product appeal, particularly in naïve users. Methods: In a crossover study with three separate study days, n = 15 occasional smokers without established cigarette or nicotine dependence consumed a mentholated HTP (mHTP), a non-mentholated HTP (nmHTP), and a conventional cigarette (CC) under ad libitum conditions during a 30 min observation. We measured plasma nicotine concentrations, smoking topography, cardiovascular parameters, and subjective effects (mCEQ). Results: Nicotine pharmacokinetics (Cmax, AUC) were comparable across products (Cmax 7.8–8.5 ng/mL; AUC 2.3–2.8 ng·min/mL [geometric means]; no significant differences), even though participants had no prior experience with HTPs. Compared to CCs, HTPs were associated with longer puff durations (2.09 s mHTP/2.00 s nmHTP vs. 1.78 s CC), higher puff volumes (mean: 68.06/68.16 vs. 43.76 mL; total: 949.80/897.73 vs. 522.41 mL), and greater flow rates (mean 37.49/38.25 vs. 27.68 mL/s; peak 63.24/63.69 vs. 44.38 mL/s). Subjective effects did not differ significantly between products (mCEQ subscale examples: satisfaction 3.00–3.33/7; reward 2.81–3.31/7; craving reduction 5.07–5.60/7). Cardiovascular parameters such as heart rate or systolic blood pressure showed with no between-product differences (HR p = 0.518; SBP p = 0.109) and no differences in their change over time between products (HR p = 0.807; SBP p = 0.734). No differences were observed between mHTP and nmHTP. Conclusion: HTPs can deliver nicotine and evoke user experiences similar to CCs, even in non-dependent users. The more intensive inhalation behavior observed with HTPs may reflect compensatory use and merits further investigation. Although no menthol-specific effects were observed, methodological constraints may have limited their detectability.

  • Open Access

    Two Different Heated Tobacco Products vs. Cigarettes: Comparison of Nicotine Delivery and Subjective Effects in Experienced Users

    by Jochen Vukas, Nadja Mallock-Ohnesorg, Tobias Rüther, Elke Pieper, Luna Romano-Brandt, Yvonne Stoll, Lukas Hoehne, Nestor Burgmann, Peter Laux, Andreas Luch, et al.

    Heated tobacco products (HTPs) produce aerosol using a different mechanism than tobacco cigarettes, leading to lower emissions of some harmful substances, but also of nicotine as reported by some independent studies. Lower nicotine delivery could lead to compensatory puffing when product use does not sufficiently satisfy cravings. Thus, this three-arm crossover study was conducted to characterize the potential of two different HTPs to deliver nicotine and satisfy cravings compared with conventional cigarettes in users who had already switched to HTPs. Fifteen active, non-exclusive HTP users consumed the study products according to a pre-directed puffing protocol. At predetermined time points, venous blood was sampled and the subjective effects of consumption were assessed. Nicotine delivery by both HTPs was comparable, but significantly lower than that by conventional cigarettes, suggesting a lower addictive potential. Cravings were reduced by all products, with no statistically significant differences between them, despite the different nicotine deliveries. This indicated that HTPs do not necessarily need high nicotine deliveries with high addictive potential, as are characteristic of tobacco cigarettes. These results were followed up on with an ad libitum use study.


  • Open Access

    Usage Pattern and Nicotine Delivery during Ad Libitum Consumption of Pod E-Cigarettes and Heated Tobacco Products

    by Andrea Rabenstein, Anna Rahofer, Jochen Vukas, Benedikt Rieder, Kristin Störzenhofecker, Yvonne Stoll, Nestor Burgmann, Elke Pieper, Peter Laux, Andreas Luch, et al.

    Many different nicotine delivery products, such as e-cigarettes (e-cigs) or heated tobacco products (HTPs), are available on the market. To better understand these products, it is crucial to learn how consumers use them and how much nicotine they deliver. Therefore, a pod e-cig, an HTP, and a conventional cigarette (CC) were each used by 15 experienced users of the respective product category for 90 min without special use instructions (“ad libitum”). Sessions were video recorded to analyze usage patterns and puff topography. At defined time points, blood was sampled to determine nicotine concentrations, and subjective effects were inquired about using questionnaires. During the study period, the CC and HTP groups averaged the same number of consumption units (both 4.2 units). In the pod e-cig group, the highest number of puffs was taken (pod e-cig 71.9; HTP: 52.2; CC: 42.3 puffs) with the most extended mean puff duration (pod e-cig: 2.8 s; HTP: 1.9 s; CC: 1.8 s). Pod e-cigs were predominantly used with single puffs or in short clusters of 2–5 puffs. The maximum plasma nicotine concentration was highest for CCs, followed by HTPs, and then pod e-cigs with 24.0, 17.7, and 8.0 ng/mL, respectively. Craving was reduced by all products. The results suggest that the high nicotine delivery known for tobacco-containing products (CCs and HTPs) may not be needed for non-tobacco-containing products (pod e-cigs) to satisfy cravings in experienced users.